CF vs SION: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CF and SION share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CF and SION exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CF Industries Holdings makes nitrogen products, primarily anhydrous ammonia, granular urea, and urea ammonium nitrate (UAN) solution, along with ammonium nitrate and diesel exhaust fluid. It is the world's largest producer of ammonia and North America's largest pure-play nitrogen manufacturer, running a fleet of gas-fed plants across the US, Canada, and the UK. Natural gas is its main feedstock, so its cost position is structurally advantaged when North American gas is cheap relative to European and Asian producers.

Full CF guide

Sionna Therapeutics (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on cystic fibrosis (CF). Its lead candidates, SION-719 and SION-451, are first-in-class stabilizers of the nucleotide-binding domain 1 (NBD1) of the CFTR protein, the region disrupted by the F508del mutation that affects roughly 90% of CF patients. The thesis is that stabilizing NBD1 could restore CFTR function toward wild-type levels and, added on top of the current standard of care (Vertex's Trikafta), deliver clinically meaningful improvement. The company went public in February 2025 at $18.00 per share, raising about $219 million in an upsized IPO.

Full SION guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CF drivers: Tight global nitrogen supply and pricing; Low-cost North American natural gas feedstock.
• SION drivers: Summer 2026 clinical readouts; Differentiated NBD1 mechanism.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CF's earnings are highly cyclical and tied to volatile nitrogen prices, which can fall sharply when global supply loosens or demand softens. For SION, as a pre-revenue clinical-stage biotech, Sionna faces the standard binary risk that a trial disappoints, which could sharply reduce the stock's value given its roughly $1.8 billion market cap sits on an unproven pipeline.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CF if you believe its drivers more; SION if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CF and SION guides.

CF. CF posted a strong Q1 2026, with net sales up about 19% to roughly $1.99 billion and net earnings near $615 million on tight global nitrogen supply and higher selling prices across all segments. The quarter included one-off items such as a litigation settlement gain and insurance recoveries. The stock trades at a low double-digit forward earnings multiple typical of a cyclical commodity producer, reflecting the market's expectation that peak-cycle earnings are not permanent.

SION. SION has no product revenue and runs steady operating losses, which is normal for a clinical-stage biotech funding trials. Traditional earnings multiples do not apply; the market is pricing the probability-weighted value of the CF pipeline. The roughly $1.8 billion market cap against about $290 million of cash implies large expectations riding on the summer 2026 data.

Headline figures (approximate, MAY 2026): CF shows revenue (ttm) ~$6.4B, q1 2026 net sales ~$1.99B, q1 2026 net earnings ~$615M, q1 2026 adjusted ebitda ~$983M; SION shows revenue (ttm) ~$0 (no approved product), net loss (fy2025) ~$75M, net loss (q1 2026) ~$27M, cash & marketable securities ~$290M (into 2028).

CF and SION are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CF and SION exposure against your real portfolio. It is not an investment adviser.